"Novel Psychopharmacology for Depressive Disorders"

Adv Exp Med Biol. 2021:1305:449-461. doi: 10.1007/978-981-33-6044-0_22.


Major depressive disorder carries a significant burden and a high risk for suicide. The need for more effective, safer, and faster-acting drugs is, therefore, compelling. The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine. A critical overview of the evidence and the pitfalls associated with current antidepressant drug development is likewise provided in the following text.

Keywords: Esketamine; Ketamine; Major depressive disorder; Novel antidepressant; Treatment resistance.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Depressive Disorder, Major* / drug therapy
  • Excitatory Amino Acid Antagonists
  • Humans
  • Psychopharmacology*


  • Antidepressive Agents
  • Excitatory Amino Acid Antagonists